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Autosomal recessive limb-girdle muscular dystrophies (LGMD type 2) are 
a group of clinically and genetically heterogeneous diseases with the main 
characteristics of weakness and wasting of the pelvic and shoulder girdle 
muscles. Among them are sarcoglycanopathies caused by mutations in at 
least four genes named SGCA, SGCB, SGCG and SGCD. Here we report a 
consanguineous Iranian family with two children affected with LGMD type 2E. 
Mutation analysis revealed a novel homozygous exon 2 deletion of SGCB gene 
in the patients with the parents being heterozygous for this deletion. This result 
presents a novel underlying genetic mechanism for LGMD type 2E.
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Introduction
Autosomal recessive limb-girdle muscular dystrophies (LGMD type 2) comprise 
a group of clinically and genetically heterogeneous diseases with the main 
characteristics of weakness and wasting of the pelvic and shoulder girdle muscles 
(1). As various LGMD subtypes are difficult to be distinguished merely by their 
clinical manifestations, a combination of immunohistochemical and immunoblot 
analyses, and subsequent DNA sequencing have been suggested for identification 
of the underlying causes (2). 
Based on the former method, LGMD can be classified to sarcoglycanopathy, 
calpainopathy, dysferlinopathy, and dystroglycanopathy subtypes (3). 
Sarcoglycan complex in skeletal muscle is made by the protein products of four 
genes namely SGCA, SGCB, SGCG and SGCD. This complex contributes to 
the stability of dystrophin-dystroglycan complex as well as the stability of the 
plasma membrane cytoskeleton (4). Overall, mutations in 16 genes have been 
associated with different types of LGMD (5). Severe childhood-onset LGMD is 
mostly associated with the mutations of SGCG, SGCA, SGCB or SGCD genes 
(LGMD2C-2F, respectively) (6). LGMD2E (MIM# 604286) has been a clinically 
heterogeneous disorder associated with both truncating and missense mutations in 
SGCB gene as well as large homozygous microdeletion of chromosome 4q11-q12 
that comprises the whole SGCB gene (7).
Case study
Here we report a consanguineous Iranian family with two children (12 
and 7 yr old) affected with LGMD (Figure 1). Both siblings suffered from 
progressive muscle weakness with clinical onset of an age of six years. 
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deleted region (NG_008891.1:g.11186_11208inv, 
c.243+1297_243+1319inv) (Figure 2). Segregation 
analysis showed that both parents are heterozygous for 
the identified mutation.
Discussion
We have identified a novel large deletion in SGCB 
gene in two patients and shown that parents were 
heterozygous for it. Previous studies have recognized 
deletions of complete exon(s) of SGCG and SGCA 
genes, and partial duplications of exon 1 of SGCB gene 
(8). However, this is the first report of complete exon 
deletion in SGCB gene. 
The existence of complete exon deletions in a certain 
gene has its implications in genetic diagnosis, especially 
for carrier detection. Therefore, such probability should 
be considered in genetic counseling of LGMD patients. 
In addition, the patients presented above had no more 
severe phenotype compared with the cases presented 
in the literature before despite the different nature of 
mutation. For instance, a missense mutation in exon 3, 
encoding for the proximal extracellular domain caused 
a severe a Duchenne-like phenotype. 
Missense mutations affecting this domain would 
lead to the instability of the entire sarcoglycan 
complex resulting in severe phenotypes as seen 
in nonsense mutations (9). Additionally, although 
shown cardiomyopathy in LGMD type 2E patients 
(10), our patients did not have any manifestations of 
cardiomyopathy at the age of 12. 
In conclusion, Future studies would help in 
establishment of genotype-phenotype correlation in 
LGMD patients that is of special importance in genetic 
counseling as well as prenatal diagnosis.
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No cardiac abnormalities were reported in their 
electrocardiography or echocardiography. The older 
sib became wheelchair-dependent by the age of 10 
yr. Their mental development was normal. Creatine 
kinase (CK) levels were elevated to 100 times of 
normal values, whereas lactate dehydrogenase (LDH) 
levels were up to 10 times of normal range. A slight 
elevation in hepatic enzyme levels was also indicated. 
The electromyogram showed typical myopathic 
changes including low-amplitude and short-duration 
action potentials. Nerve conduction studies indicated 
normal motor conduction velocities. The muscle 
biopsies showed dystrophic-like changes such as 
variability in myofiber diameters, atrophic and 
hypertrophic fibers, in addition, to increase in adipose 
and fibrous tissue.
Informed consent was taken from the family and the 
university approved the study ethically. 
In immunohistochemical studies, the complete absence 
of all four sarcoglycans was indicated. In order to find 
underlying genetic cause, genomic DNA was extracted 
from blood samples of the patients using the standard 
salting out method after informed consent. Sequence 
analysis was performed using NimbleGen chip 
capturing of LGMD related genes followed by Next 
Generation Sequencing (BGI-Clinical Laboratories, 
Shenzhen, China). Homozygous deletion of SGCB 
exon 2 was detected in the patients. 
In order to delineate deletion boundaries, long-range 
PCR, and chromosomal walking technique were used. 
For this reason, genomic DNA of patient and parents 
was amplified with different primer pairs. Ultimately, 
the primer pairs 5’-TCCCCACCCTGCATTTGAA-3’ 
and 5’-GGCATGTTATTCTTGTTTCATTGA-3’ 
that correspond to adjacent introns respectively, 
showed the deletion boundaries. PCR conditions 
were as follows: an initial denaturation step at 95 
°C for 2 min, 30 cycles of 95 ºC for 30 sec, 56.1 ºC 
for 30 sec and 72 ºC for 5 min, and a final extension 
step at 72 °C for 5 min. Sanger sequence analysis of 
the corresponding segment in the proband showed a 
2082 bp deletion (NG_008891.1:g.9104_11184del, 
c.34-576_243+1295del, p.Gln12_Ile81del) as well 
as insertion of a 23 nucleotide segment which is 
reverse complement of a segment adjacent to the 
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